Biophytis SA (FR:ALBPS) has released an update.
Biophytis SA has reported positive outcomes from their Phase 2-3 COVA study, indicating a significant reduction in the risk of early respiratory failure or death by 43.8% and a 44.6% decrease in the death rate over 90 days for severe COVID-19 cases. The study’s results were presented at the World Congress on Infectious Diseases in Paris, positioning their drug candidate BIO101 as a potential treatment for severe COVID-19, especially in the elderly with co-morbidities. Despite the ongoing pandemic, the company’s CEO emphasized the underestimated global COVID-19 figures and the drug’s independence from specific virus strains.
For further insights into FR:ALBPS stock, check out TipRanks’ Stock Analysis page.
